RUNX1 and acute myeloid leukemia: In contrast to AML1-ETO1-driven AML, a comparison of 16 NPM1c+-driven AML patient samples with 14 samples from patients with clinical remission using RTL-P revealed a decrease at the four sites analyzed (i.e., 28S-Cm1327, 28S-Cm3866, 28S-Um3904, and 28S-Gm4198).